Fort Sheridan Advisors LLC Intellia Therapeutics, Inc. Transaction History

Fort Sheridan Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $3,763 - $5,182	158 Added 2.16%	7,478 $205,000
Q1 2023 May 12, 2023	BUY	$33.3 - $44.82 $13,319 - $17,928	400 Added 5.78%	7,320 $272,000
Q2 2022 Aug 08, 2022	BUY	$38.49 - $76.21 $48,497 - $96,024	1,260 Added 22.26%	6,920 $358,000
Q1 2021 May 17, 2021	BUY	$46.59 - $83.68 $2,748 - $4,937	59 Added 1.05%	5,660 $454,000
Q4 2020 Feb 16, 2021	BUY	$18.83 - $63.53 $105,466 - $355,831	5,601 New	5,601 $305,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Fort Sheridan Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Fort Sheridan Advisors LLC with notifications on news.